Lu Xu

1.9k total citations
47 papers, 1.4k citations indexed

About

Lu Xu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lu Xu has authored 47 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lu Xu's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (4 papers). Lu Xu is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (4 papers). Lu Xu collaborates with scholars based in China, United Kingdom and South Korea. Lu Xu's co-authors include R.Z. Wang, S.L. Qi, Hongzhuan Chen, Qingnan Zhao, Ling Li, Caiyun Wang, Chun Zhang, Liang Zhu, Huiming Xiong and Ling Li and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Nano Letters.

In The Last Decade

Lu Xu

44 papers receiving 1.4k citations

Peers

Countries citing papers authored by Lu Xu

Since Specialization

Citations

This map shows the geographic impact of Lu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Xu more than expected).

Fields of papers citing papers by Lu Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Xu. The network helps show where Lu Xu may publish in the future.

Co-authorship network of co-authors of Lu Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Xu. A scholar is included among the top collaborators of Lu Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Xu. Lu Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subthalamic nucleus oscillations during facial emotion processing and apathy in Parkinson's disease 2025 ·Journal of Affective Disorders ·Jun Li, Linbin Wang, Yixin Pan, Peng Huang, Lu Xu, Yuyao Zhang, Dirk De Ridder, Valerie Voon, Dianyou Li	0
2	Systematic characterization and efficient prediction of cobalamin C deficiency clinical phenotypes using network analysis and deep learning on multi-omics data 2024 ·Microchemical Journal ·Zeyu Li, Xiaoying Liu, Wen Xiao, (unknown), Panpan Jiang, Benqing Wu, Xiangju Liu, (unknown), Haibin Lv, Shuaishuai Zhou, Qin Yang, Lu Xu, Yanling Yang	0
3	A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression 2024 ·Acta Pharmaceutica Sinica B ·Cheng Wang, Minghao Zhang, Shunyao Li, (unknown), (unknown), (unknown), (unknown), (unknown), Lu Xu, Hui-min Lei, Ling Bi, Liang Zhu, Zhengting Wang, Hongzhuan Chen, Lu Zhou, Ying Shen	2
4	Metagenomic next-generation sequencing and proteomics analysis in pediatric viral encephalitis and meningitis 2023 ·Frontiers in Cellular and Infection Microbiology ·Yilong Wang, (unknown), (unknown), (unknown), Xuebin Xu, (unknown), Lu Xu, (unknown), (unknown), Xin Zhang, (unknown), (unknown), (unknown), Feng Gao	3
5	AMFR drives allergic asthma development by promoting alveolar macrophage–derived GM-CSF production 2022 ·The Journal of Experimental Medicine ·(unknown), Ran Wei, Xinyi Yang, Lu Xu, (unknown), (unknown), Haixia Jiang, Haibo Zhang, Zhi Hong Chen, Feng Qian, Lei Sun	28
6	Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma 2022 ·Cancer Research ·(unknown), Ye Zhou, (unknown), Cheng Wang, (unknown), (unknown), (unknown), Ya‐Bin Tang, Qian Liang, (unknown), Lu Xu, Pengfei Ma, Guanglei Zhuang, Ling Bi, Ling Xu, Liang Zhu, Hongzhuan Chen, Ying Shen	42
7	Effects of Unilateral Stimulation in Parkinson's Disease: A Randomized Double-Blind Crossover Trial 2022 ·Frontiers in Neurology ·(unknown), Linbin Wang, (unknown), Lu Xu, Zhengyu Lin, (unknown), Peng Huang, Yixin Pan, (unknown), Yun Ling, Kang Ren, Chencheng Zhang, Bomin Sun, Dianyou Li	4
8	Proteomic profiling of cerebrospinal fluid in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease 2022 ·World Journal of Pediatrics ·Yilong Wang, (unknown), (unknown), Xiaoyan Ren, (unknown), (unknown), Lu Xu, (unknown), (unknown), Xin Zhang, (unknown), (unknown), Zhengyan Zhao, Feng Gao	9
9	Risk factors for brain metastases in patients with non-small cell lung cancer: a meta-analysis of 43 studies 2021 ·Annals of Palliative Medicine ·Shanshan Chen, Xin Hua, (unknown), (unknown), Shuzhen Wei, Lu Xu, Shuhua Han, Hongming Zhang, Xiaoli Zhu	14
10	Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway 2020 ·Frontiers in Oncology ·Ling Li, Tao Wang, (unknown), Yali Zhang, Hongzhuan Chen, Lu Xu	27
11	MK2 Is Required for Neutrophil-Derived ROS Production and Inflammatory Bowel Disease 2020 ·Frontiers in Medicine ·Tao Zhang, (unknown), Jingting Liu, Lu Xu, Shixin Duan, Lei Sun, Wenjuan Zhao, Feng Qian	34
12	Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy 2020 ·Frontiers in Oncology ·Ling Li, (unknown), Tao Wang, Hongzhuan Chen, Lu Xu	25
13	Invasive mucinous adenocarcinoma of the lung 2019 ·Translational Cancer Research ·Lu Xu, Chenghui Li, Hongyang Lu	27
14	Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3 2018 ·Oncogene ·(unknown), (unknown), Caiyun Wang, Ling Li, Qingnan Zhao, Hongzhuan Chen, Lu Xu	70
15	Acid-induced aggregation propensity of nivolumab is dependent on the Fc 2016 ·mAbs ·Boning Liu, Huaizu Guo, Jin Xu, Ting Qin, Lu Xu, Junjie Zhang, Qingcheng Guo, Dapeng Zhang, Weizhu Qian, Bohua Li, Jianxin Dai, Sheng Hou, Yajun Guo, Hao Wang	40
16	ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma 2016 ·Tumor Biology ·Lu Xu, Xin Tong, Sujie Zhang, Fan Yin, Xiaoyan Li, Huafeng Wei, Cheng Li, Yajun Guo, Jian Zhao	13
17	Application of an innovative computerized virtual planning system in acetabular fracture surgery: A feasibility study 2016 ·Injury ·Huixiang Wang, Fang Wang, Simon Newman, Yanping Lin, Xiaojun Chen, Lu Xu, Qiugen Wang	24
18	Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) 2015 ·Cancer Biology & Therapy ·Qingnan Zhao, (unknown), Chun Zhang, Qin Lu, Hongzhuan Chen, Lu Xu	33
19	Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET 2012 ·Cancer Research ·Lu Xu, Eiki Kikuchi, Chunxiao Xu, Hiromichi Ebi, Dalia Ercan, Katherine A. Cheng, Robert F. Padera, Jeffrey A. Engelman, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura, Kwok‐Kin Wong	88
20	Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells 2011 ·Cancer Letters ·Yang Ma, Qinqin Cheng, (unknown), Lu Xu, Ying Zhao, Jie Sun, Siyi Hu, Weihua Xiao	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact